First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction
Morie A. Gertz(Mayo Clinic in Arizona), Michaela Liedtke(Cancer Prevention Institute of California), David C. Seldin(Boston University), Raymond L. Comenzo(Memorial Sloan Kettering Cancer Center), Jeffrey A. Zonder(The Barbara Ann Karmanos Cancer Institute), Stefan Schönland(AOL (United States)), Gene G. Kinney(United States Military Academy), Spencer Guthrie(Heidelberg University), Giampaolo Merlini(University of Pavia), Martin Koller(Heidelberg University), Dale B. Schenk(Heidelberg University), Heather Landau(Memorial Sloan Kettering Cancer Center), Jackie Walling(Heidelberg University), Brendan M. Weiss(Heidelberg University)
Cited by 206
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k